Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Brief Summary: This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record.

The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).


Options:
A: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Ozanimod1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Interferon β-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ozanimod placebo, Drug: Interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg | Intervention Type: DRUG; Name: Ozanimod placebo; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a placebo; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg
B: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
C: Arm Label: Group 1: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 1: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 2: Washout then DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 2: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 3: Washout then DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 3: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Group 1: DAC HYP 150 mg, Group 1: DAC HYP 300 mg, Group 2: DAC HYP 150 mg, Group 2: Washout then DAC HYP 150 mg, Group 3: DAC HYP 300 mg, Group 3: Washout then DAC HYP 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Washout then DAC HYP 150 mg, Group 3: Washout then DAC HYP 300 mg
D: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab

Answer: A